Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05032066
Other study ID # HZNP-HZN-825-303
Secondary ID 2021-001253-32
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date August 25, 2021
Est. completion date July 2025

Study information

Verified date February 2024
Source Horizon Pharma Ireland, Ltd., Dublin Ireland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

HZNP-HZN-825-303 (HARBOR) comprises of 2 parts. Part 1 (Core Phase) is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial to evaluate the efficacy, safety and tolerability of HZN-825 in participants with Idiopathic Pulmonary Fibrosis (IPF). Part 2 (Extension Phase) is an optional, open-label, repeat-dose, multicenter extension of the Core Phase. The trial will include up to an 8-week Screening Period and a 52-week Double-blind Treatment Period in the Core Phase and 52 weeks of open-label HZN-825 treatment in the Extension Phase. During the Core Phase, participants will be screened within 8 weeks prior to the baseline (Day 1) Visit. Approximately 135 participants who meet the trial eligibility criteria will be randomly assigned in a 1:1:1 ratio on Day 1 to receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally for 52 weeks using the following 2 stratification factors: 1. Concomitant use of approved IPF therapy (i.e., nintedanib or pirfenidone): yes or no 2. Forced vital capacity (FVC) % predicted at Baseline: ≥70% or <70% Participants who complete the 52-week Double blind Treatment Period of the Core Phase of the trial will be invited to extend their participation in the 52-week Extension Phase of the trial.


Description:

Part 1 (Core Phase) The overall objective of the Core Phase is to investigate the efficacy, safety and tolerability of 2 dose regimens of HZN-825, a selective antagonist of lysophosphatidic acid receptor-1 (LPAR1), administered orally once daily (QD) or twice daily (BID) for 52 weeks in the treatment of participants with IPF. Part 2 (Extension Phase) The overall objective of the Extension Phase is to investigate the long-term efficacy, safety and tolerability of HZN-825, a selective antagonist of LPAR1, administered at a dose of 300 mg BID orally to participants with IPF in a 52-week open-label extension (OLE) following completion of the Core Phase of the trial. The dose for the Extension Phase may be modified based on the results of the Core Phase. Two types of Baseline are defined for the Extension Phase: - OLE Baseline, defined as the latest measurement prior to the first dose of HZN-825 in the Extension Phase - HZN-825 Baseline, defined as the latest measurement prior to the first dose of HZN-825 in either the Core Phase or the Extension Phase. For subjects who received placebo in the Core Phase, OLE Baseline will be the same as HZN-825 Baseline.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 153
Est. completion date July 2025
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria in Core Phase: 1. Male or female =18 years of age at Screening. 2. Current diagnosis of IPF, as defined by American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Society (ALAT) guidelines and determined by central review; the date of initial diagnosis of IPF should be =7 years prior to Screening. 3. No recent changes or planned changes to the dose or regimen for IPF therapy, defined as: - Receiving a stable dose of IPF-approved therapy (i.e., nintedanib or pirfenidone) for a minimum of 3 months prior to Day 1 with no plans to change the background regimen during trial participation, or - Not currently receiving background IPF-approved therapy at Screening (either naïve to IPF-approved therapy or previously discontinued any IPF-approved therapy at least 4 weeks prior to Day 1 or drug-specific, 5 half-lives elimination period if longer than 4 weeks), and with no current plans to restart treatment during trial participation - Participants receiving any additional agent for IPF therapy must be on a stable regimen for at least 3 months prior to Day 1 with no current plans to change the treatment regimen during trial participation. Any previously discontinued therapy used to treat IPF must have been discontinued at least 4 weeks prior to Day 1 or 5 half-lives for that specific therapy must have elapsed, whichever is longer, with no plans to restart the therapy during trial participation. 4. Lung high-resolution computed tomography (HRCT) historically performed within 6 months prior to the Screening Visit and according to the minimum requirements for IPF diagnosis by central review based on participant's HRCT. If an evaluable HRCT is not available within 6 months prior to Screening, an HRCT will be performed at Screening to determine eligibility, according to the same requirements as the historical HRCT. 5. HRCT shows =10% to <50% parenchymal fibrosis (reticulation) and the extent of fibrotic changes is greater than the extent of emphysema on the most recent HRCT scan (central reviewer determined). 6. Meets all of the following criteria during the Screening Period: 1. FVC =45% predicted of normal 2. forced expiratory volume in 1 second (FEV1)/FVC =0.7 3. Diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for hemoglobin is =25% and =90% predicted of normal 7. Estimated minimum life expectancy of =30 months for non-IPF-related disease, in the opinion of the Investigator. 8. Vaccinations are up to date given age, comorbidities and local availability prior to trial drug dosing. 9. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial. Key Inclusion Criteria in Extension Phase: 1. Completed the Double-blind Treatment Period (Week 52) of the Core Phase of the trial; subjects prematurely discontinued from trial drug in the Core Phase of the trial for reasons other than safety or tolerability may be included at the discretion of the Investigator after completing scheduled visits, including Week 52 assessments. 2. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the Extension Phase of the trial. Key Exclusion Criteria Core Phase: 1. Any of the following cardiovascular diseases: 1. uncontrolled, severe hypertension (=160/100 mmHg), within 6 months of Screening 2. myocardial infarction within 6 months of Screening 3. unstable cardiac angina within 6 months of Screening 2. Interstitial lung disease (ILD) associated with known primary diseases (e.g., sarcoidosis, amyloidosis and coronavirus disease 2019 [COVID-19]), connective tissue disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus, Sjogren's, dermatomyositis, scleroderma), exposures (e.g., radiation, silica, asbestos and coal dust) or drugs (e.g., amiodarone). 3. Known active bacterial, viral, fungal, mycobacterial or other infection, including tuberculosis or atypical mycobacterial disease (fungal infections of nail beds are allowed). The participant must be 3 months beyond any acute infection with COVID-19 if there has been a prior infection. 4. Clinically significant pulmonary hypertension requiring chronic medical therapy. 5. Use of any of the following therapies within 4 weeks prior to Screening, during the Screening Period or planned during the trial: prednisone at steady dose >10 mg/day or equivalent or cyclosporine. Change in regimen or dosage of any immunosuppressant during the Screening Period through the end of trial participation will require consultation with and approval by the trial Medical Monitor. 6. Use of rifampin within 2 weeks prior to Day 1 or planned during the trial. 7. Malignant condition in the past 5 years (except successfully treated basal/squamous cell carcinoma of the skin or cervical cancer in situ). 8. Women of childbearing potential (WOCBP) or male subjects not agreeing to use highly effective method(s) of birth control throughout the trial and for 4 weeks after last dose of trial drug. Females must refrain from egg/ova donation for 4 weeks after the last dose of trial drug and males must refrain from sperm donation for 3 months after the last dose of trial drug. 9. Pregnant or lactating women and women who plan to become pregnant or breast feed during the trial and within 4 weeks after the last dose of trial drug. 10. Current drug or alcohol abuse or history of either within the previous 2 years, in the opinion of the Investigator or as reported by the subject. 11. Previous enrollment in this trial or participation in a prior HZN-825 or SAR100842 clinical trial. 12. Known history of positive test for human immunodeficiency virus (HIV). 13. Active hepatitis (hepatitis B: positive hepatitis B surface antigen and positive anti-hepatitis B core antibody [anti-HBcAb] and negative hepatitis B surface antibody [HBsAb] or positive for HBcAb with a positive test for HBsAb and with presence of hepatitis B virus DNA at Screening; hepatitis C: positive anti-hepatitis C virus [anti-HCV] and positive RNA HCV). 14. Current alcoholic liver disease, primary biliary cirrhosis or primary sclerosing cholangitis. 15. Previous organ transplant (including allogeneic and autologous marrow transplant). 16. International normalized ratio >2, prolonged prothrombin time >1.5 × the upper limit of normal (ULN) or partial thromboplastin time >1.5 × ULN at Screening. 17. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.0 × ULN. 18. Estimated glomerular filtration rate <30 mL/min/1.73 m^2 at Screening. 19. Total bilirubin >1.5 × ULN. Subjects with documented diagnosis of Gilbert's syndrome may be enrolled if their total bilirubin is =3.0 mg/dL. 20. Moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment according to the Child-Pugh scoring system. 21. Any confirmed Grade 3 or higher laboratory abnormality. 22. Any laboratory abnormality at Screening that, in the opinion of the Investigator, would preclude the participant's entry in the trial. 23. Exposure to an experimental drug (with the exception of HZN-825) or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is the longest, prior to Day 1. 24. Any other condition that, in the opinion of the Investigator, would preclude enrollment in the trial. Key Exclusion Criteria Extension Phase: 1. Anticipated use of another investigational agent for any condition during the course of the trial. 2. New diagnosis of malignant condition after enrolling in Trial HZNP-HZN-825-303 (except successfully treated basal/squamous cell carcinoma of the skin or cervical cancer in situ). 3. Estimated minimum life expectancy =18 months, in the opinion of the Investigator.

Study Design


Intervention

Drug:
HZN-825
Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema. Extension Phase: Participants will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks.
Placebo
Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema. Extension Phase: Participants who received matching placebo in the Core Phase will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks.

Locations

Country Name City State
Argentina STAT Research S.A. Ciudad Autónoma de Buenos Aires Buenos Aires
Argentina Centro Medico Dra de Salvo Ciudad de Buenos Aires
Argentina Instituto De Enfermedades Respiratorias E Investigacion Medica Florencio Varela Buenos Aires
Argentina Instituto Ave Pulmo Mar Del Plata Buenos Aires
Argentina Instituto De Patologías Respiratorias San Miguel De Tucumán Tucumán
Argentina Instituto Del Buen Aire Santa Fe
Australia Royal Adelaide Hospital Adelaide South Australia
Australia Box Hill Hospital Box Hill Victoria
Canada Dynamic Drug Advancement Ltd. Ajax Ontario
Canada St. Joseph's Healthcare Hamilton Hamilton Ontario
Chile Centro de Investigación Curico Curico Maule
Chile Universidad de Los Andes Las Condes Región-MetropolitanadeSantiago
Chile MIRES/MYF estudios cli-nicos Ñuñoa Región-MetropolitanadeSantiago
Chile Enroll SpA Providencia Región-MetropolitanadeSantiago
Chile Centro Respiratorio Integral LTDA. (CENRESIN) Quillota Valparaíso
Chile Meditek Ltda Santiago Región-MetropolitanadeSantiago
Chile Centro de Investigacion del Maule Talca
Chile Clinical Research Chile SpA Valdivia
France Hopital Nord AP-HM Marseille Bouches-du-Rhône
France Hopital Haut Leveque Pessac Gironde
France Hôpital Bretonneau Tours Indre-et-Loire
Germany Lungenklinik Hemer Hemer Nordrhein-Westfalen
Greece Evangelismos General Hospital of Athens Athens Attiki
Greece University General Hospital of Ioannina Ioannina
Greece University General Hospital of Heraklion Iraklio
Greece University General Hospital of Larissa Larisa
Greece Athens Medical Center Marousi Attiki
Greece University General Hospital of Patras Patras Achaïa
Italy Presidio Ospedaliero GB Morgagni L Pierantoni Forlì Emilia-Romagna
Italy Azienda Ospedaliera Universitaria Senese Siena
Japan National Hospital Organization Himeji Medical Center Himeji-Shi Hyôgo
Japan Hiroshima Prefectural Hospital Hiroshima
Japan National Hospital Organization Ibarakihigashi National Hospital Naka-Gun Ibaraki
Japan National Hospital Organization Kinki-Chuo Chest Medical Center Sakai-Shi Ôsaka
Japan Medical Hospital of Tokyo Medical and Dental University Tokyo
Japan Kanagawa Cardiovascular and Respiratory Center Yokohama-Shi Kanagawa
Korea, Republic of Seoul National University Bundang Hospital Seongnam-si Gyeonggido
Korea, Republic of Asan Medical Center-PPDS Seoul
Korea, Republic of Korea University Anam Hospital Seoul
Korea, Republic of Samsung Medical Center Seoul
Mexico Oaxaca Site management Organization (OSMO) Centro Oaxaca
Mexico CICUM San Miguel Guadalajara Jalisco
Mexico Hospital Universitario Dr. Jose Eleuterio González Monterrey Nuevo León
Mexico Unidad de Investigación Clínica En Medicina SC Monterrey Nuevo León
Netherlands Erasmus MC Rotterdam
Poland Uniwersyteckie Centrum Kliniczne Gdansk Pomorskie
Poland PULMAG Grzegorz Gasior Marzena Kociolek Spolka Cywilna Katowice Slaskie
Poland MCM Krakow - PRATIA - PPDS Kraków
South Africa Dr. Ismail Abdullah Private Practice Cape Town Western Cape
South Africa University of Cape Town Lung Institute (UCTLI) Cape Town Western Cape
South Africa KwaPhila Health Solutions Durban Kwazulu - Natal
Spain Hospital Universitario de Bellvitge L'Hospitalet De Llobregat Barcelona
Spain Hospital Universitario 12 de Octubre Madrid
Spain Hospital Universitario Quironsalud Madrid Pozuelo De Alarcón Madrid
Taiwan Kaohsiung Medical University - Chung-Ho Memorial Hospital Kaohsiung City
Taiwan China Medical University Hospital - PPDS Taichung
Taiwan Far Eastern Memorial Hospital Taipei
Taiwan Taipei Veterans General Hospital Taipei
Turkey Kocaeli University Hospital Kocaeli
United Kingdom Connolly Hospital Blanchardstown Liverpool
United States University of Alabama at Birmingham Birmingham Alabama
United States St. Francis Medical Institute Clearwater Florida
United States The Cleveland Clinic Foundation Cleveland Ohio
United States Stony Brook Medicine Advanced Specialty Care Commack New York
United States El Paso Pulmonary Association - Elligo El Paso Texas
United States Clinical Trials Center of Middle Tennessee Franklin Tennessee
United States Clinical Research of Gastonia Gastonia North Carolina
United States University of Kansas Medical Center Kansas City Kansas
United States Dartmouth Hitchcock Medical Center Lebanon New Hampshire
United States Nebraska Pulmonary Specialties LLC Lincoln Nebraska
United States Metroplex Pulmonary and Sleep Medicine Center McKinney Texas
United States Northwestern Memorial Hospital Milwaukee Wisconsin
United States Vanderbilt University Medical Center Nashville Tennessee
United States Central Florida Pulmonary Group PA Orlando Florida
United States Palmtree Clinical Research Palm Springs California
United States Temple University Hospital Philadelphia Pennsylvania
United States Thomas Jefferson University Philadelphia Pennsylvania
United States Clinical Research of Rock Hill Rock Hill South Carolina
United States Shelby Clinical Research Shelby North Carolina
United States DBC Research Corp. Tamarac Florida
United States GCP Clinical Research Tampa Florida
United States Southeastern Research Center Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Horizon Therapeutics Ireland DAC

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Canada,  Chile,  France,  Germany,  Greece,  Italy,  Japan,  Korea, Republic of,  Mexico,  Netherlands,  Poland,  South Africa,  Spain,  Taiwan,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Core Phase: Change in Forced Vital Capacity (FVC) percent (FVC %) predicted from Baseline to Week 52 Baseline to Week 52
Primary Extension Phase: Change from the Open Label Extension (OLE) baseline, defined as the latest measurement prior to the first dose of HZN-825 in the extension phase in FVC % predicted from Baseline to Week 104 Baseline to Week 104
Primary Extension Phase: Change from the HZN-825 baseline, defined as the latest measurement prior to the first dose of HZN-825 in either the core phase or the extension phase in FVC % predicted from Baseline to Week 104 Baseline to Week 104
Secondary Core Phase: Change from baseline in the 6MWT (Six-Minute Walk Test) results to Week 52 The 6-minute walk test measures the distance that a participant can quickly walk on a flat, hard surface in 6 minutes. This test evaluates the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units and muscle metabolism. The 6MWT will be performed according to ATS guidelines for the 6MWT. Baseline to Week 52
Secondary Core Phase: Change from baseline in K-BILD (King's Brief Interstitial Lung Disease) scores to Week 52 The King's Brief Interstitial Lung Disease Questionnaire is a self-completed health status questionnaire comprising 15 items and a 7-point Likert response scale that was developed and validated specifically for patients with IPF. The questionnaire has 3 domains: psychological, breathlessness, and activities and chest symptoms. The K-BILD domains and total score range from 0 to 100; 100 represents best health status. The minimal clinically important difference for the K-BILD total score as determined by both anchor and distribution methods is a change of 5 units. Baseline to Week 52
Secondary Core Phase: Change from baseline in L-IPF (Living with IPF[Idiopathic Pulmonary Fibrosis]) scores to Week 52 The questionnaire evaluates how living with IPF has impacted the quality of life of the participant with IPF. There are two modules, a 15-item symptom module with 3 domains (dyspnea, cough, and energy) all with a 24-hour recall and a 20-item impacts module with 1-week recall. All items in both modules have response options in a 5-point (0-4) numerical rating scale, where 0 = not at all and 4 = all the time. Baseline to Week 52
Secondary Core Phase: Change from baseline in LCQ (Leicester Cough Questionnaire) scores to Week 52 The LCQ is a participant-reported questionnaire evaluating the impact of cough on quality of life. The LCQ comprises 19 items and takes 5-10 minutes to complete. Each item assesses symptoms or the impact of symptoms over the last 2 weeks on a 7-point Likert scale. Scores in 3 domains (physical, psychological, and social) are calculated as a mean for each domain (range: 1-7). A total score (range: 3 to 21) is also calculated. Higher scores indicate better quality of life. Baseline to Week 52
Secondary Core Phase: Time to first hospitalization due to respiratory distress up to Week 52 Baseline to Week 52
Secondary Core Phase: Time to first onset of the composite endpoint of PFS (progression-free survival) from Baseline up to Week 52, where progression includes decline in FVC % predicted =10% or death Baseline to Week 52
Secondary Core Phase: Incidence of treatment emergent adverse events (TEAEs) Day 1 to Week 52
Secondary Core Phase: Incidence of serous adverse events (SAEs) Day 1 to Week 52
Secondary Core Phase: Incidence of adverse events of special interest (AESIs): orthostatic hypotension Day 1 to Week 52
Secondary Core Phase: Incidence and frequency of use of concomitant medication(s) Day 1 to Week 52
Secondary Core Phase: Change in abnormal and clinically significant vital signs as reported as TEAEs Day 1 to Week 52
Secondary Core Phase: Change in abnormal clinical safety laboratory test results as reported as TEAEs Day 1 to Week 52
Secondary Core Phase: Change in abnormal and clinically significant 12-lead electrocardiogram (ECG) or echocardiogram measurements as reported as TEAEs. Day 1 to Week 52
Secondary Extension Phase: Incidence of AESIs: orthostatic hypotension Day 1 to Week 104
Secondary Extension Phase: Incidence of TEAEs Day 1 to Week 104
Secondary Extension Phase: Incidence and frequency of use of concomitant medication(s) Baseline to Week 104
Secondary Extension Phase: Change from trial baseline in abnormal and clinically significant vital signs reported as TEAEs Baseline to Week 104
Secondary Extension Phase: Change from trial baseline in abnormal and clinically significant 12-lead ECG) measurements as reported as TEAEs. Baseline to Week 104
Secondary Extension Phase: Change from trial baseline in abnormal clinical safety laboratory test results as reported as TEAEs Baseline to Week 104
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05984992 - The First-in-human Study of SRN-001 in Healthy Participants Phase 1
Active, not recruiting NCT04312594 - Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT03865927 - GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03979430 - Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study N/A
Enrolling by invitation NCT04905693 - Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Phase 3
Terminated NCT04419558 - Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 3
Completed NCT03725852 - A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Terminated NCT03573505 - An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT04148157 - Quality of Life in IPF - Patient and Physician Perceptions
Active, not recruiting NCT03222648 - Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis N/A
Completed NCT02257177 - RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients Phase 1/Phase 2
Completed NCT02268981 - Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF) N/A
Withdrawn NCT01524068 - A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations Phase 2
Enrolling by invitation NCT01382368 - Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Phase 4
Completed NCT01199887 - Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis Phase 1
Completed NCT01110694 - Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
Active, not recruiting NCT02951416 - Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
Terminated NCT00981747 - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Phase 2/Phase 3
Completed NCT00532233 - SD, IL-13 Production Rate in IPF Phase 2
Completed NCT00540475 - Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry